



A pre-seed stage company developing an active implant to stimulate baroreceptors for Heart Failure (HF) patients, through a minimally invasive approach



Technology

A trans-vessel active implant for baroreceptors stimulation to regulate heart rate and blood pressure in patients with Heart Failure and cardiovascular disease. Venous catheterization takes advantage of the close proximity of the jugular vein and carotid sinuses for a safe, quick, and easy procedure. Cardionyx offers for the first-time personalized baroreceptor stimulation with real-time hemodynamic monitoring extending life-span & improving quality of life for HF patients.

Preclinical proof

Proven capability to stimulate baroreceptors via catheterization of an adjacent vein.

Market

The baro-stimulation market for HF stands at \$1.4B, serving 55K severe patients (NYHA III-IV), and \$2.2B for 76K mild patients (NYHA II).

Funding

\$700K raised as SAFE 08/23. Seeking to secure \$1.3M in pre-seed funding.

Team

Cardionyx is led by cardiologist Ilan Marcuschamer, MD. R&D is managed by Jonathan Yahalom and advised by Dr. David Yakobi, Dr. Tuvia Ben Gal & Prof. Ran Kornowsky.